Drug-coated balloon in-stent restenosis treatment is now in the U.S., and its poised to have a major impact. See how, in this Cardiac Wire Show interview with @bostonsci’s Janarthanan Sathananthan, MD, FSCAI.

Check out the latest Cardiac Wire Show with @Merative's @BobSchallhorn and @KLASresearch’s @MqueRasband detailing how cath labs are changing, and how hemodynamic monitoring is keeping up.

@Novartis @OrchestraBioMed @rwyeh @FalahBatla @NielsRoyen @MaeharaAkiko @MortenLamberts @TorBiering @Milan_M_98 @AnnaKateBarton @neiljcraig @justvick @BrittanMairi @damini_dey @Piotr_JSlomka

It seems even interventional cardiologists aren’t immune to the “Weekend Effect” as a recent study suggests patients admitted on weekends for TAVR procedures face significantly higher risks.

@813JAFERD @Eko_Health @CureMetrix @Volpara @ArashNargesi @LovedeepDhingra @hmkyale @rohan_khera @mvaduganathan @gcfmd @rwyeh @TorBiering @rkwadhera @hunter_mehaffey @AworiHayanga @RameshDaggubati @MPeyT1 @ArenillasJF @DoctorGaldamez

Sooner certainly seems to be better than later when it comes to treating LDL-C levels with the PCSK9 inhibitor evolocumab (Amgen’s Repatha), and according to a recent JACC study, that’s especially true for older patients.

The cardiac RPM arena has undergone a massive evolution, and new technologies suggest that an even greater shift is coming up. Tune in to the latest Cardiac Wire Show with Ken Nelson for a deep dive into the next frontier of cardiac digital health.

@biomeanalytics @Philips @STS_CTsurgery @viz_ai @kevin_volpp @joeltramo @JSawallaGusehMD @KrishnaAragam @patrick_ellinor @shaan_khurshid @dan_atar

Another year, another AHA report reasserting heart disease’s dominance as the number one killer in the United States, and the latest data shows that this trend is still gaining momentum.

@DrNathanWong @SallySWong @KristineYaffe @MdNitsche @DaniTomasoni_ @MasriAhmadMD @FinnGustafsson @MicheleEmdin @MarcoMetra @scottdsolomon @dr_m_fontana @ZaidAlMarzooq @MTiburcy

@AVS_PIVL @KoshiroSakai_MD @DoosupShin @djc795 @JWMoses @ColletCarlos @ESHLOF @DrAllenJ @OKhaliqueMD @HoumanJalaie @SethShayMartin @ZaidAlMarzooq @CarissaBakerSm1 @NishaKidneyDoc @ycommodore @SaynaNorouzi @kardiologykazi @darae_ko @sarahmperman @MPStOngePhD

@HMRI_Pasadena @ArtivionInc @joinBunkerhill @oisoliman @dirkwestermann @VoskuilMichiel @AOskar @Eric_Van_Belle @MMontorfanoOSR @VlasisNinios @ignamatsant @NielsRoyen @DrMoritzWvB @VinodThourani @JoeSabik @hwijeysundera @Dr_ChrisSimpson @TimAndersonMD

Anthos Therapeutics published the results of its Phase 2 AZALEA-TIMI 71 trial for its novel Factor XI inhibitor, abelacimab, confirming the drug’s lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients.

@JonPicciniSr @bostonsci @BooneHeart @HeartFlow @ThijsEijsvogels @ortegaporcel @marcusflather @SPatelMD @rantocran @spjuraschek

Although GLP-1s have proven to significantly help with weight loss and cardiometabolic disorders, a new Nature Medicine study shed light on the drugs’ potential side-effects.